Day: March 31, 2023

TORONTO, March 30, 2023 (GLOBE NEWSWIRE) — Jamieson Wellness Inc. (“Jamieson Wellness” or the “Company”) (TSX: JWEL) announced today that the Company has filed its management information circular (“Circular”) and related materials (together with the Circular, the “Meeting Materials”) for the annual and special meeting of shareholders (the “Shareholders”) of Jamieson Wellness to be held on May 18, 2023 at 2:00 p.m. (Eastern Daylight Time) at the offices of McCarthy Tetrault LLP, 66 Wellington Street West, Toronto, Ontario, Suite 5300, and online via live audio webcast at https://meetnow.global/MMUNSXJ (the “Meeting”). The Company is pleased to be offering Shareholders the option to participate in-person at this year’s Meeting, while continuing to offer Shareholders the option to participate online via live audio webcast. The Meeting...

SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) — OMNIQ Corp. (NASDAQ: OMQS) (“OMNIQ” or “the Company”), a provider of Artificial Intelligence (AI) and IoT – based solutions announces record breaking revenue with Full Year 2022 of $102.5M an all-time high and a Q4 of $25M.  ● Record Revenue of $102.5 Million a 31% YoY increase       ● Record Gross Profit of $22.1 Million an increase of $5.4 Million or 33% over FY 2021       ● Positive Cash Flow from Operations of $1.2 Million compared to a deficit of $3.2M in FY 2021       ● AI Machine Vision Revenue increased by more than 100% compared to FY 2021 driven by strong customer demand across Public Safety, Automation of Parking and Retail and Quick Service Restaurants       ● Company completed the acquisition of 100% of Dangot Computers Ltd., a leader in providing...

PLANO, Texas, March 30, 2023 (GLOBE NEWSWIRE) — Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snack and eating platform disrupting traditional consumer packaged goods (CPG) categories, and a leader in the air-dried meat snack industry in the United States, today announces that it will release its fiscal 2022 fourth quarter and full year results on Monday, April 3, 2023, before the market opens, and host a conference call on that same day at 9:00am ET. In addition to a discussion around 2022 performance, management will provide fiscal 2023 guidance for select financial measures, an overview of its capital plans, as well as commentary regarding meaningful distribution wins, as a result of, improvements in product quality, its retail strategy, and brand positioning that are expected to support...

TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that three additional detailed analyses from the Phase IIb clinical study (Study 201), evaluating the efficacy and safety of lecanemab for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD), were published in the peer-reviewed journals.Detailed results on biomarker, cognitive, and clinical effects from Study 201 core to OLE (open-label extension): Alzheimer’s Research and Therapy Consistency of efficacy results across various clinical measures and statistical methods in Study 201:...

TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai presented new analyses on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and caregiver burden and health-related quality of life (QOL), from the results of Eisai’s Phase 3 Clarity AD study of lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti-amyloid-β (Aβ) protofibril* antibody, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases annual meeting AD/PD™. Clarity AD was a global confirmatory Phase 3 placebo-controlled,...